The thoracic oncology community is discussing the negative results of the CheckMate 73L trial, where nivolumab-based consolidation strategies failed to improve PFS or OS versus standard durvalumab consolidation in unresectable stage III NSCLC. Separately, real-world data on neoadjuvant chemoimmunotherapy for early-stage NSCLC is showing results similar to those from pivotal trials, with a pCR rate of 30% and high rates of R0 resection.
“In a ph3 trial, nivolumab + CCRT followed by nivolumab ± ipilimumab failed to improve PFS or OS vs standard CCRT followed by durvalumab in unresectable stage III NSCLC.”
— @diegoadiazg · CheckMate 73L Results · View post ↗📌 Amplified by @KolPulseAI
“Real world results from Alberta, Canada on neoadjuvant chemoimmunotherapy for early stage NSCLC @ClinicalLung similar to trials: 86% underwent surgery, pCR rate 30%, nearly all pts achieving R0 resection.”
— @StephenVLiu · Real-World Neoadjuvant IO Data · View post ↗
“Long-term follow-up isn’t the end of a trial, it’s where the real conversation begins.”
— @NarjustFlorezMD · Long-Term Trial Follow-Up · View post ↗📌 Amplified by @KolPulseAI
The oncology community is discussing the ASCENT-03 and ASCENT-04 trials of sacituzumab govitecan with or without pembrolizumab in first-line metastatic triple-negative breast cancer (mTNBC). There is also conversation around patient selection for ovarian function suppression (OFS) in premenopausal women with early-stage HR-positive breast cancer, with the greatest benefit seen in higher-risk patients.
“Not every premenopausal woman with early-stage HR-positive breast cancer requires ovarian function suppression (OFS).”
— @DrRupamOncology · Ovarian function suppression · View post ↗The GI oncology community is discussing results from ESMOGI26, including two notable negative trials. The KRYSTAL-10 trial of adagrasib plus cetuximab missed its primary endpoint in second-line KRAS G12C mCRC, and the phase III IRIGA trial found first-line FOLFIRINOX did not beat mFOLFOX6 in advanced gastric/GEJ adenocarcinoma. In pancreatic cancer, early data for zoldonrasib plus chemotherapy showed promising activity, with a Phase III trial now underway.
“KRYSTAL-10: Adagrasib + cetuximab misses its primary endpoint in 2L KRAS G12C mCRC.”
— @GIMedOnc · KRYSTAL-10 trial · View post ↗📌 Amplified by @KolPulseAI
“Can first-line FOLFIRINOX beat mFOLFOX6 in HER2-negative advanced gastric/GEJ adenocarcinoma? At #ESMOGI26, the phase III IRIGA trial says: not in the overall population.”
— @DrRishabhOnco · IRIGA trial · View post ↗
“🧬 KRAS G12D is no longer an “undruggable” target.”
— @DraMartinezLago · KRAS G12D targeting · View post ↗📌 Amplified by @KolPulseAI
The GU oncology community is discussing the FDA approval of pembrolizumab for the adjuvant management of renal cell carcinoma (RCC), with commentary on toxicity profiles and quality of life. Separately, physicians noted the now-strong international consensus to use PSMA PET/CT as the standard staging tool in high-risk prostate cancer.
“Overall toxicity ⬆️ with belzutifan but irAE rates similar. Will addition of a targeted therapy impact HRQoL? Or will ICI remain the driver for 'Life Changing' tox?”
— @BethN01 · Toxicity in Adjuvant RCC Therapy · View post ↗📌 Amplified by @KolPulseAI
“Controversial then, settled now: I remember when PSMA PET/CT was not recommended - concern of Will Roger's "Stage Migration".”
— @DrMHofman · PSMA PET/CT Consensus · View post ↗
“baseline midlife PSA blows away race and family history and genes as a predictor of prostate cancer mortality.”
— @VickersBiostats · Prostate Cancer Screening · View post ↗The myeloma/hematology community is discussing new sub-analyses from the CASSIOPEIA trial. One analysis used transcriptomic profiling to identify risk categories and refine the value of MRD, while another suggested patients with t(11;14) have slower initial response rates but a favorable long-term prognosis. Other topics include survival data in smoldering myeloma and the GPRC5D therapy talquetamab in the MonumenTAL-3 trial.
“Transcriptomic profiling of CASSIOPEIA pts identified 5 subtypes & 3 risk categories w/ 72-month PFS rates of 70%/51%/27% & refined value of MRD by identifying high-risk pts in whom MRD was insufficient to predict outcome:”
— @Myeloma_Doc · CASSIOPEIA trial sub-analysis · View post ↗📌 Amplified by @KolPulseAI
“Results from CASSIOPEIA trial suggest pts w/ cyclin D1 overexpression & t(11;14) exhibit slower response rates after induction & high-dose therapy in setting of triplet or quads but long-term prognosis remains favorable:”
— @Myeloma_Doc · CASSIOPEIA trial t(11;14) sub-analysis · View post ↗
“Talquetamab Steps Forward: MonumenTAL-3 - A New Potential for GPRC5D Therapy in #Myeloma | EHA 2026”
— @MyelomaTeacher · Talquetamab / MonumenTAL-3 · View post ↗📌 Amplified by @KolPulseAI
The hematology community is discussing strategies for optimizing HMA and venetoclax therapy in AML, including the OPTI-AML trial investigating a shorter 14-day venetoclax cycle. New data also shows that signaling mutations can negate the favorable prognosis of NPM1 in older AML patients receiving this combination. In DLBCL, a post-hoc analysis suggests the tumor microenvironment, specifically low M1-like macrophage infiltration, may explain the benefit of polatuzumab vedotin with R-CHP.
“Signaling mutations negate the favorable impact of NPM1 in older patients with AML treated with HMA/VEN.”
— @FiekeHoff · AML prognostic factors · View post ↗
“low M1-like macrophage infiltration = worse PFS/OS with R/GCHOP, but NOT prognostic with pola-R-CHP”
— @majorajay · DLBCL biomarkers · View post ↗
“OPTI-AML: Phase II Trial of 28-Day vs 14-Day Venetoclax and Azacitidine for 2 Cycles in Patients Aged ≥60 Years with Newly Diagnosed Genomically Agnostic AML”
— @smbenlazar · AML clinical trial · View post ↗📌 Amplified by @KolPulseAI